1,020
Participants
Start Date
November 1, 2023
Primary Completion Date
November 1, 2025
Study Completion Date
May 1, 2028
Long term survival multimodal analysis
"* To describe global signatures (Digital histology, Radiomic, Genomic, Transcriptomic, Proteomic, (Epigenomic) and clinical signature) that are associated with a patient's unexpected survival compared to standard patients across three cohorts of solid tumors with unmet medical needs.~* To describe global signatures in the overall population (pan-cohort).~* To describe clinical, digital pathology, radiomic, genomic, transcriptomic, proteomic and epigenomic signatures associated with patients' unexpected survival compared to standard patients for each cohort and in all cohorts (pan-cohort)"
RECRUITING
Gustave Roussy Cancer Campus, Grand Paris, Villejuif
Gustave Roussy, Cancer Campus, Grand Paris
OTHER
Centre Leon Berard
OTHER
Vall d'Hebron Institute of Oncology
OTHER
Istituto Europeo di Oncologia
OTHER
Charite University, Berlin, Germany
OTHER
Cure 51
OTHER